Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Phase 1 Study Evaluating Pharmacokinetics (PK) and Safety of Carfilzomib in Patients with Advanced Malignancies and Varying Degrees of Hepatic Impairment (HI)

Jennifer Brown, Ruth Plummer, Stephen Anthony, John Sarantopoulos, Filip De Vos, Mike White, Marco Schupp, Ying Ou, Ulka Vaishampayan

Blood (2016) 128 (22): 4496.

https://doi.org/10.1182/blood.V128.22.4496.4496

Published: 2016

Journal Articles

ZAP-70 Disrupts Dipeptidyl Peptidase 2 (DPP2)-Regulated Quiescence in Chronic Lymphocytic Leukemia (CLL).

Alexey V. Danilov, MD, PhD, Olga Danilova, MD, PhD, Andreas Klein, MD, Jennifer Brown, MD, PhD, Arthur P. Rabinowitz, MD, Kenneth B Miller, MD, Brigitte T Huber, PhD

Blood (2009) 114 (22): 1251.

https://doi.org/10.1182/blood.V114.22.1251.1251

Published: 2009

Journal Articles

An Ongoing Phase 1 Study of ABT-263; Pharmacokinetics, Safety and Anti-Tumor Activity in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Andrew W. Roberts, MBBS, PhD, Jennifer Brown, MD, PhD, John F. Seymour, M.D., William G. Wierda, M.D., Ph.D, Thomas J. Kipps, MD, PhD, Hao Xiong, Ph.D., Yi-Lin Chiu, PhD, Todd Busman, PhD, Raymond A. Knight, MBA, Sari Enschede, MD, Andrew Krivoshik, MD, PhD, Rod Humerickhouse, MD, PhD

Blood (2008) 112 (11): 3177.

https://doi.org/10.1182/blood.V112.11.3177.3177

Published: 2008

Journal Articles

Analysis of Minimal Residual Disease (MRD) from the Phase 2 Multicenter Study of Subcutaneous (SC) Alemtuzumab Combined with Fludarabine for Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (CLL).

Christopher Flowers, Hilary Rosenthal, Jennifer Brown, Wendy Stock, Harvey Katzen, Shailendra Lakhanpal, David Jaye

Blood (2007) 110 (11): 3111.

https://doi.org/10.1182/blood.V110.11.3111.3111

Published: 2007

Journal Articles

Characterization of Pica in Adults with Sickle Cell Disease.

Rupa Redding-Lallinger, MD, Norman Gray, MD, Oludamolola Olajide, MD, Juana Diaz, Jennifer Brown, Diedra Ansah

Blood (2005) 106 (11): 3785.

https://doi.org/10.1182/blood.V106.11.3785.3785

Published: 2005

NARROW

A Phase 1 Study Evaluating Pharmacokinetics (PK) and Safety of Carfilzomib in Patients with Advanced Malignancies and Varying Degrees of Hepatic Impairment (HI)

ZAP-70 Disrupts Dipeptidyl Peptidase 2 (DPP2)-Regulated Quiescence in Chronic Lymphocytic Leukemia (CLL).

An Ongoing Phase 1 Study of ABT-263; Pharmacokinetics, Safety and Anti-Tumor Activity in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Analysis of Minimal Residual Disease (MRD) from the Phase 2 Multicenter Study of Subcutaneous (SC) Alemtuzumab Combined with Fludarabine for Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (CLL).

Characterization of Pica in Adults with Sickle Cell Disease.

Email alerts

ASH Publications

American Society of Hematology

A Phase 1 Study Evaluating Pharmacokinetics (PK) and Safety of Carfilzomib in Patients with Advanced Malignancies and Varying Degrees of Hepatic Impairment (HI)

ZAP-70 Disrupts Dipeptidyl Peptidase 2 (DPP2)-Regulated Quiescence in Chronic Lymphocytic Leukemia (CLL).

An Ongoing Phase 1 Study of ABT-263; Pharmacokinetics, Safety and Anti-Tumor Activity in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Analysis of Minimal Residual Disease (MRD) from the Phase 2 Multicenter Study of Subcutaneous (SC) Alemtuzumab Combined with Fludarabine for Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (CLL).

Characterization of Pica in Adults with Sickle Cell Disease.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only